Slides
Page 1
Third Quarter 2026 Earnings EARNINGS PRESENTATION October 28, 2026
Page 2
2 Forward Looking Statements and Non-GAAP Financial Measures FORWARD-LOOKING STATEMENTS Statements in this presentation that are not strictly historical, including statements regarding anticipated financial results, global and regional economic conditions, industry trends, geopolitical events, anticipated product introductions, future acquisitions, impact of trade and spending policies, impact of geopolitical conflict, the ability to execute the planned strategies, interest rate and current exchange rate impact, future prospects, shareholder value, and any other statements identified by their use of words like “anticipate,” “expect,” “believe,” “outlook,” “guidance,” "target", or “will” or other words of similar meaning, are “forward-looking statements" within the meaning of the United States federal securities laws. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: deterioration of or instability in the economy, the markets we serve, international trade policies and deteriorating trade relations with other countries, including imposition of tariffs and retaliatory tariffs between United States and China and other countries, responsive economic nationalism, trade restrictions, and enhanced regulation, impact of any prolonged government shutdown, the financial markets, geopolitical conditions and conflicts including in the Middle East and in Ukraine, security breaches, data exfiltration, or other disruptions of our information technology systems, supply chain constraints, our ability to adjust purchases and manufacturing capacity to reflect market conditions, impact of development, deployment, and use of artificial intelligence, reliance on sole sources of supply, contractions or lower growth rates and cyclicality of markets we serve, competition, changes in industry standards and governmental regulations, our ability to recruit and retain key employees, our ability to successfully identify, consummate, integrate and realize the anticipated value of appropriate acquisitions or otherwise effectively deploy our capital, our ability to develop and successfully market new products, software, and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, contingent liabilities relating to acquisitions and divestitures, impact of changes to tax laws, our compliance with applicable laws and regulations and changes in applicable laws and regulations, risks relating to international economic, geopolitical, including war and sanctions, legal, compliance and business factors, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, the impact of our debt obligations on our operations, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to adequately protect our intellectual property rights, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, commodity costs and surcharges, adverse effects of restructuring activities, risk related to tax treatment of our prior separations, impact of our indemnification obligation to Ralliant and Vontier, impact of changes to U.S. GAAP, labor matters, and disruptions relating to man-made and natural disasters and climate change. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q for the subsequent quarters. T hese forward-looking statements speak only as of the date of this presentation, and Fortive does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. NON-GAAP FINANCIAL MEASURES This presentation contains references to financial measures not presented in accordance with generally accepted accounting principles (“GAAP”). We have not reconciled forward-looking targets or outlook regarding non-GAAP measures because any corresponding GAAP measures and the reconciliations thereto would require us to make estimates or assumptions with precision about acquisitions, currency transactions, capital and other expenditures and similar adjustments during the relevant period. Information required by Regulation G with respect to historical non-GAAP financial measures are set forth in the appendix to this presentation and the "Investors" section of our website, www.fortive.com, under the heading "Financial Results". PRECISION TECHNOLOGIES SEPARATION On June 28, 2025, the Company completed the separation (the “Separation”) of its former Precision Technologies ("PT") segment by distributing to Fortive shareholders on a pro rata basis all of the issued and outstanding common stock of Ralliant Corporation (“Ralliant”), the entity incorporated to hold the PT businesses. The accounting requirements for reporting Ralliant as a discontinued operation were met when the Separation was completed. Accordingly, the accompanying financial information for all periods presented reflect this business as a discontinued operation. Unless otherwise indicated, all references in this report refer to continuing operations. All growth or period changes refer to year-over-year comparisons unless otherwise stated. Forward looking financial information not otherwise presented as a range reflect assumptions underlying the midpoint of our forward-looking targets.
Page 3
3 1 Strong Q3 financial performance and execution by Fortive team, delivering +7.2% core growth, ~10% adjusted EBITDA growth and ~13% adjusted EPS growth 2 Deployed ~$300 million to share repurchases in Q3, bringing total share repurchases since the launch of new Fortive to ~$2.3 billion, consistent with our disciplined capital allocation approach 3 Fortive Accelerated strategy contributing to growth acceleration, reinforcing confidence in medium-term financial framework and value creation opportunity 4 Raising FY 2026 adjusted EPS guidance to $3.10 to $3.14, up ~15% year-over-year at the midpoint, reflecting strong year-to-date performance and confidence in the trajectory of the business Key Messages
Page 4
4 n Fortive Accelerated Strategy 1 Faster Profitable Organic Growth • Innovation Acceleration • Commercial Acceleration • Recurring Customer Value Powered by FBS Amplified 2 Disciplined Capital Allocation • Invest in organic growth • Smaller bolt-on M&A • Share repurchases • Modest growing dividend 3 Build and Maintain Investor Trust • Clear expectations and consistent delivery • Simplified guidance and disclosure • Do what we say we will do Recent new product introductions and commercial investments translating into core growth acceleration; continued strength in recurring revenue growth Demonstrated progress Deployed ~$2.3 billion to share repurchases since launch of new Fortive, representing ~43 million shares or ~13% of diluted shares outstanding1 Revamped bolt-on M&A engine in place, executing on opportunities that meet rigorous strategic and financial criteria Revamped internal financial processes for better forecast accuracy Redesigned investor messaging and guidance framework Delivered solid performance in every quarter since the July 2025 launch of new Fortive Ambition: 3-5 Year Total Shareholder Return > the S&P 500 Index2 1. Calculated based on shares outstanding at the end of Q3 2026 as compared to shares outstanding at the end of Q2 2025. 2. Represents management’s goal and not a forecast.
Page 5
5 Q3 2026 Revenue Reported Growth Core Growth $1,107.5M +7.8% +7.2% Adj. Gross Profit Adj. Gross Profit Growth (YoY) Adj. Gross Margin $692.6M +6.5% 62.5% Adj. EBITDA Adj. EBITDA Growth (YoY) Adj. EBITDA Margin $338.8M +9.5% 30.6% Adj. EPS Adj. EPS Growth (YoY) $0.77 13.2% Trailing Twelve Month (TTM) Free Cash Flow TTM FCF Conversion on Adj. Net Income $1,062.0 +109.5% Fortive Results Q3 2026 5 COMMENTARY • Core revenue growth of +7.2%, led by strong performance in IOS segment • Adj. Gross Margin of 62.5%, down ~80 bps year-over-year, driven primarily by product mix, partially offset by operating leverage • Adj. EBITDA grew ~10% year-over-year, reflecting adjusted gross profit growth, operating leverage and discrete structural cost savings, partially offset by growth investments; Adj. EBITDA margin expanded ~50 bps to 30.6% • Adj. EPS grew ~13% year-over-year, driven by Adj. EBITDA growth and favorable impact of share repurchases, partially offset by higher interest and tax expense • TTM Free Cash Flow Conversion on Adj. Net Income >100%
Page 6
6 Q3 2026 Revenue Reported Growth Core Growth $767.1M +9.8% +9.1% Adj. Gross Profit Adj. Gross Profit Growth (YoY) Adj. Gross Margin $496.9M +8.3% 64.8% Adj. EBITDA Adj. EBITDA Growth (YoY) Adj. EBITDA Margin $274.7M +13.6% 35.8% Intelligent Operating Solutions Q3 2026 6 COMMENTARY • Core revenue growth of +9.1%, driven by acceleration in professional instrumentation, Facilities and Asset Lifecycle solutions and gas detection • Adj. Gross Margin of ~65%, similar to Q2, and down ~90 bps year-over-year, driven primarily by product mix, partially offset by operating leverage • Adj. EBITDA grew ~14%, driven by adjusted gross profit growth, operating leverage and discrete structural cost savings, partially offset by growth investments • Adj. EBITDA margin expanded by ~120 basis points year-over-year to ~36%
Page 7
7 Q3 2026 Revenue Reported Growth Core Growth $340.4M +3.7% +3.1% Adj. Gross Profit Adj. Gross Profit Growth (YoY) Adj. Gross Margin $195.7M +2.1% 57.5% Adj. EBITDA Adj. EBITDA Growth (YoY) Adj. EBITDA Margin $87.9M (4.8)% 25.8% Advanced Healthcare Solutions Q3 2026 7 COMMENTARY • Core revenue growth of +3.1%, driven by solid demand for healthcare consumables and SaaS offerings, with modest growth in capital equipment • Adj. Gross Margin of ~58%, down about 90 bps year-over-year, driven primarily by product mix, partially offset by operating leverage • Adj. EBITDA Margin of ~26%, ~flat sequentially and down YoY, driven by growth investments and the year-over- year headwind from discrete cost benefits in Q3'25, partially offset by operating leverage
Page 8
8 Balance Sheet & Capital Allocation Q3 2026 Balance Sheet As of October 2, 2026 Cash and equivalents $0.38B Gross Debt, principal amounts $3.53B Net Debt $3.15B Leverage Q3 2026 TTM Adj. EBITDA $1.33B Gross Debt / Adj. EBITDA ~2.6X Net Debt / Adj. EBITDA ~2.4X Cash Flow TTM as of October 2, 2026 TTM Operating Cash Flow $1,176.6M TTM Capital Expenditures ($114.6M) TTM Free Cash Flow $1,062.0M TTM Free Cash Conversion on Adj. Net Income 109.5% COMMENTARY & CAPITAL ALLOCATION HIGHLIGHTS • Deployed ~$300 million towards share repurchase in Q3, representing ~5M shares, at an average price of $60.14 • Increased regular quarterly dividend by ~17% year-over-year in Q3 • Reduced leverage to 2.6x Gross Debt / Adjusted EBITDA • Robust Free Cash Flow generation provides further capacity and flexibility to execute our capital deployment priorities, always with a disciplined focus on allocating capital to optimize shareholder returns over the medium to long term 8
Page 9
9 Adj. EPS | FY 2026 $3.10 to $3.14 Raising FY 2026 Guidance Guidance as of date of Q3 2026 earnings call: October 28, 2026.
Page 10
10 Innovating essential technologies to keep our world safe and productive Fortive Accelerated
Page 11
11 Appendix & Supplemental Reconciliation Data
Page 12
12 CORE REVENUE GROWTH AND REVENUE BY GEOGRAPHY 12 Three Months Ended October 2, 2026 Intelligent Operating Solutions Advanced Healthcare Solutions Total Fortive Total revenue growth (GAAP) 9.8 % 3.7 % 7.8 % Excluding impact of: Acquisitions and divestitures (0.4) % (0.5) % (0.5) % Currency exchange rates (0.3) % (0.1) % (0.1) % Core revenue growth (Non-GAAP) 9.1 % 3.1 % 7.2 % Contribution to core growth: Price 2.1 % 2.8 % 2.3 % Volume 7.0 % 0.3 % 4.9 % Three Months Ended $ in millions Intelligent Operating Solutions Advanced Healthcare Solutions Total Fortive October 2, 2026 September 26, 2025 Change (%) October 2, 2026 September 26, 2025 Change (%) October 2, 2026 September 26, 2025 Change (%) North America $ 483.2 $ 433.2 11.5 % $ 194.9 $ 191.5 1.8 % $ 678.1 $ 624.7 8.5 % Asia-Pacific 117.8 111.4 5.7 % 74.8 70.0 6.9 % 192.6 181.4 6.2 % Europe, Middle East, and Africa 135.1 126.3 7.0 % 41.6 41.6 — % 176.7 167.9 5.2 % Latin America 31.0 27.9 11.1 % 29.1 25.2 15.5 % 60.1 53.1 13.2 % Total Revenue (GAAP) 767.1 698.8 9.8 % 340.4 328.3 3.7 % 1,107.5 1,027.1 7.8 %
Page 13
13 Three Months Ended October 2, 2026 Three Months Ended September 26, 2025 $ in millions Intelligent Operating Solutions Advanced Healthcare Solutions Total Fortive Intelligent Operating Solutions Advanced Healthcare Solutions Total Fortive Revenue (GAAP) $ 767.1 $ 340.4 $ 1,107.5 $ 698.8 $ 328.3 $ 1,027.1 Gross Profit (GAAP) $ 514.2 $ 196.4 $ 710.6 $ 457.5 $ 191.7 $ 649.2 Adjustments Discrete Restructuring Charges — — — 1.4 — 1.4 IEEPA tariff refunds (17.3) (0.7) (18.0) — — — Total Adjustments (Non-GAAP) $ (17.3) $ (0.7) $ (18.0) $ 1.4 $ — $ 1.4 Adjusted Gross Profit (Non-GAAP) $ 496.9 $ 195.7 $ 692.6 $ 458.9 $ 191.7 $ 650.6 Gross Profit Margin (GAAP) 67.0 % 57.7 % 64.2 % 65.5 % 58.4 % 63.2 % Adjusted Gross Profit Margin (Non-GAAP) 64.8 % 57.5 % 62.5 % 65.7 % 58.4 % 63.3 % 13 ADJUSTED GROSS PROFIT AND ADJUSTED GROSS PROFIT MARGIN
Page 14
14 ADJUSTED EBITDA AND ADJUSTED EBITDA MARGIN FROM CONTINUING OPERATIONS Three Months Ended $ in millions October 2, 2026 July 3, 2026 April 3, 2026 December 31, 2025 September 26, 2025 Revenue (GAAP) $ 1,107.5 $ 1,096.8 $ 1,069.4 $ 1,122.5 $ 1,027.1 Net Earnings from Continuing Operations (GAAP) $ 172.5 $ 157.3 $ 136.4 $ 191.5 $ 117.0 Interest expense, net 38.8 35.4 31.6 31.0 25.4 Income taxes 29.8 22.2 27.2 2.4 18.0 Depreciation 22.6 22.0 20.4 18.1 17.6 Amortization 89.3 91.5 93.2 93.2 91.5 EBITDA (Non-GAAP) 353.0 328.4 308.8 336.2 269.5 Pretax acquisition, divestiture, and Separation related items (a) 1.0 1.4 1.9 2.1 38.3 Pretax discrete restructuring charges 1.5 2.4 6.3 18.5 2.1 Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt (4.9) (4.6) (3.3) 1.2 (0.5) Pretax IEEPA tariff refunds (18.0) (4.5) — — — Pretax capitalized software impairment 6.2 — — — — Pretax gain from divestiture — — — (0.1) — Adjusted EBITDA (Non-GAAP) $ 338.8 $ 323.1 $ 313.7 $ 357.9 $ 309.4 Trailing Twelve Months Adjusted EBITDA (Non-GAAP) as of October 2, 2026 $ 1,333.5 Net Earnings Margin from Continuing Operations (GAAP) 15.6 % 14.3 % 12.8 % 17.1 % 11.4 % Adjusted EBITDA Margin (Non-GAAP) 30.6 % 29.5 % 29.3 % 31.9 % 30.1 % (a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Net earnings from continuing operations. The sum of the components of adjusted EBITDA may not equal due to rounding. 14
Page 15
15 Three Months Ended $ in millions October 2, 2026 September 26, 2025 Revenue (GAAP) $ 1,107.5 $ 1,027.1 Operating Profit (GAAP) $ 235.9 $ 159.6 Amortization of acquisition-related intangible assets 89.3 91.5 Acquisition, divestiture, and Separation related items (a) 1.0 38.3 Discrete restructuring charges 1.5 2.1 IEEPA tariff refunds (18.0) — Capitalized software impairment 6.2 — Adjusted Operating Profit (Non-GAAP) 315.9 291.5 Depreciation 22.6 17.6 Other 0.3 0.3 Adjusted EBITDA (Non-GAAP) $ 338.8 $ 309.4 Operating Profit Margin (GAAP) 21.3 % 15.5 % Adjusted Operating Profit Margin (Non-GAAP) 28.5 % 28.4 % Adjusted EBITDA Margin (Non-GAAP) 30.6 % 30.1 % (a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs. The sum of the components of adjusted operating profit may not equal due to rounding. 15 OPERATING PROFIT & OPERATING PROFIT MARGIN TO ADJUSTED EBITDA AND ADJUSTED MARGIN BRIDGE
Page 16
16 Three Months Ended October 2, 2026 Three Months Ended September 26, 2025 $ in millions Intelligent Operating Solutions Advanced Healthcare Solutions Unallocated Corporate Costs & Other Total Fortive Intelligent Operating Solutions Advanced Healthcare Solutions Unallocated Corporate Costs & Other Total Fortive Revenue (GAAP) $ 767.1 $ 340.4 $ — $ 1,107.5 $ 698.8 $ 328.3 $ — $ 1,027.1 Operating Profit (GAAP) $ 223.4 $ 38.2 $ (25.7) $ 235.9 $ 180.7 $ 42.5 $ (63.6) $ 159.6 Adjustments Amortization of acquisition-related intangible assets 44.7 44.6 — 89.3 46.4 45.1 — 91.5 Acquisition, divestiture, and Separation related items (a) 0.4 0.2 0.4 1.0 0.1 0.1 38.1 38.3 Discrete restructuring charges 0.7 — 0.8 1.5 2.0 0.1 — 2.1 IEEPA tariff refunds (17.3) (0.7) — (18.0) — — — — Capitalized software impairment 6.2 — — 6.2 — — — — Total Adjustments (Non-GAAP) 34.7 44.1 1.2 80.0 48.5 45.3 38.1 131.9 Adjusted Operating Profit (Non-GAAP) 258.1 82.3 (24.5) 315.9 229.2 87.8 (25.6) 291.5 Depreciation 16.6 5.6 $ 12.7 $ 4.5 Adjusted EBITDA (Non-GAAP) $ 274.7 $ 87.9 $ 241.9 $ 92.3 Operating Profit Margin (GAAP) 29.1 % 11.2 % 25.9 % 12.9 % Adjusted Operating Profit Margin (Non-GAAP) 33.6 % 24.2 % 32.8 % 26.7 % Adjusted EBITDA Margin (Non-GAAP) 35.8 % 25.8 % 34.6 % 28.1 % (a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs. The sum of the components of adjusted operating profit may not equal due to rounding. 16 SEGMENT ADJUSTED EBITDA AND SEGMENT ADJUSTED EBITDA MARGIN
Page 17
17 ADJUSTED NET EARNINGS AND ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS Three Months Ended $ in millions, except per share amounts October 2, 2026 September 26, 2025 Per share value Per share value Net Earnings and Earnings Per Share from Continuing Operations (GAAP) $ 172.5 $ 0.57 $ 117.0 $ 0.35 Pretax amortization of acquisition related intangible assets 89.3 0.29 91.5 0.27 Pretax acquisition, divestiture, and Separation related items (a) 1.0 — 38.3 0.11 Pretax discrete restructuring charges 1.5 — 2.1 0.01 Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt (4.9) (0.02) (0.5) — Pretax IEEPA tariff refunds (18.0) (0.06) — — Pretax capitalized software impairment 6.2 0.02 — — Tax effect of the adjustments reflected above (12.2) (0.03) (20.1) (0.06) Adjusted Net Earnings and Adjusted Earnings Per Share from Continuing Operations (Non-GAAP) $ 235.4 $ 0.77 $ 228.3 $ 0.68 Average Common Diluted Stock Outstanding (shares in millions) 303.9 333.4 (a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Net earnings from continuing operations. Percentages presented elsewhere may not recalculate based on the amounts shown due to rounding. 17
Page 18
18 $ in millions October 2, 2026 Current portion of long-term debt, carrying value $ — Long-term debt, carrying value 3,514.2 Debt, net carrying value (GAAP) 3,514.2 Plus: Aggregate unamortized debt discounts, premiums, and issuance costs 17.8 Debt, principal amounts 3,532.0 Less: Cash and equivalents 377.3 Net debt (Non-GAAP) $ 3,154.7 TTM Adjusted EBITDA (Non-GAAP) $ 1,333.5 Gross Leverage 2.6X Net Leverage 2.4X DEBT PRINCIPAL, NET DEBT, AND LEVERAGE 18
Page 19
19 Three Months Ended Trailing Twelve Months$ in millions October 2, 2026 July 3, 2026 April 3, 2026 December 31, 2025 Operating Cash Flows from Continuing Operations (GAAP) $ 313.3 $ 298.7 $ 220.4 $ 344.2 $ 1,176.6 Less: Purchases of property, plant & equipment (capital expenditures) (GAAP) (29.5) (28.1) (26.6) (30.4) (114.6) Free Cash Flow (Non-GAAP) $ 283.8 $ 270.6 $ 193.8 $ 313.8 $ 1,062.0 Adjusted Net Earnings from Continuing Operations (Non-GAAP) $ 235.4 $ 228.5 $ 217.5 $ 288.9 $ 970.3 Free Cash Flow Conversion on Adjusted Net Earnings from Continuing Operations 120.6 % 118.4 % 89.1 % 108.6 % 109.5 % Three Months Ended Trailing Twelve MonthsSeptember 26, 2025 June 27, 2025 March 28, 2025 December 31, 2024 Operating Cash Flows from Continuing Operations (GAAP) $ 294.7 $ 205.0 $ 191.8 $ 327.7 $ 1,019.2 Less: Purchases of property, plant & equipment (capital expenditures) (GAAP) (28.6) (25.0) (21.1) (22.6) (97.3) Free Cash Flow (Non-GAAP) $ 266.1 $ 180.0 $ 170.7 $ 305.1 $ 921.9 Adjusted Net Earnings from Continuing Operations (Non-GAAP) $ 228.3 $ 197.8 $ 191.1 $ 279.8 $ 897.0 Free Cash Flow Conversion on Adjusted Net Earnings from Continuing Operations 116.6 % 91.0 % 89.3 % 109.0 % 102.8 % FREE CASH FLOW FROM CONTINUING OPERATIONS 19
Page 20
20 ADJUSTED P&L Three Months Ended October 2, 2026 Intelligent Operating Solutions Advanced Healthcare Solutions Unallocated Corporate Costs & Other Total Fortive $ in millions, except per share amounts GAAP Adjust- ments Adjusted (Non-GAAP) GAAP Adjust- ments Adjusted (Non-GAAP) GAAP Adjust- ments Adjusted (Non-GAAP) GAAP Adjust- ments Adjusted (Non-GAAP) Revenue $ 767.1 $ — $ 767.1 $ 340.4 $ — $ 340.4 $ — $ — $ — $ 1,107.5 $ — $ 1,107.5 Cost of sales (252.9) 17.3 (270.2) (144.0) 0.7 (144.7) — — — (396.9) 18.0 (414.9) Gross profit 514.2 (17.3) 496.9 196.4 (0.7) 195.7 — — — 710.6 (18.0) 692.6 Operating expenses (290.8) 52.0 (238.8) (158.2) 44.8 (113.4) (25.7) 1.2 (24.5) (474.7) 98.0 (376.7) Operating Profit $ 223.4 $ 34.7 $ 258.1 $ 38.2 $ 44.1 $ 82.3 $ (25.7) $ 1.2 $ (24.5) $ 235.9 $ 80.0 $ 315.9 Interest expense, net (38.8) — (38.8) Other non-operating income, net 5.2 (4.9) 0.3 Earnings from continuing operations before income taxes 202.3 75.1 277.4 Income taxes (29.8) (12.2) (42.0) Net earnings from continuing operations $ 172.5 $ 62.9 $ 235.4 Average Common Diluted Stock Outstanding (shares in millions) 303.9 — 303.9 Earnings Per Share from Continuing Operations $ 0.57 $ 0.20 $ 0.77 Operating Profit $ 223.4 $ 34.7 $ 258.1 $ 38.2 $ 44.1 $ 82.3 $ (25.7) $ 1.2 $ (24.5) $ 235.9 $ 80.0 $ 315.9 Depreciation 16.6 — 16.6 5.6 — 5.6 0.4 — 0.4 22.6 — 22.6 Other 0.3 — 0.3 0.3 — 0.3 Adjusted EBITDA (Non-GAAP) $ 274.7 $ 87.9 $ (23.8) $ 338.8 20
Page 21
21 ADJUSTED P&L Three Months Ended September 26, 2025 Intelligent Operating Solutions Advanced Healthcare Solutions Unallocated Corporate Costs & Other Total Fortive $ in millions, except per share amounts GAAP Adjust- ments Adjusted (Non-GAAP) GAAP Adjust- ments Adjusted (Non-GAAP) GAAP Adjust- ments Adjusted (Non-GAAP) GAAP Adjust- ments Adjusted (Non-GAAP) Revenue $ 698.8 $ — $ 698.8 $ 328.2 $ — $ 328.2 $ — $ — $ — $ 1,027.0 $ — $ 1,027.0 Cost of sales (241.3) (1.4) (239.9) (136.5) 0.7 (137.2) — — — (377.8) (0.7) (377.1) Gross profit 457.5 1.4 458.9 191.7 (0.7) 191.0 — — — 649.2 0.7 649.9 Operating expenses (276.8) 47.1 (229.7) (149.2) 46.0 (103.2) (63.6) 38.1 (25.5) (489.6) 131.2 (358.4) Operating Profit $ 180.7 $ 48.5 $ 229.2 $ 42.5 $ 45.3 $ 87.8 $ (63.6) $ 38.1 $ (25.5) $ 159.6 $ 131.9 $ 291.5 Interest expense, net (25.4) — (25.4) Other non-operating income, net 0.8 (0.5) 0.3 Earnings from continuing operations before income taxes 135.0 131.4 266.4 Income taxes (18.0) (20.1) (38.1) Net earnings from continuing operations $ 117.0 $ 111.3 $ 228.3 Average Common Diluted Stock Outstanding (shares in millions) 333.4 — 333.4 Earnings Per Share from Continuing Operations $ 0.35 $ 0.33 $ 0.68 Operating Profit $ 180.7 $ 48.5 $ 229.2 $ 42.5 $ 45.3 $ 87.8 $ (63.6) $ 38.1 $ (25.5) $ 159.6 $ 131.9 $ 291.5 Depreciation 12.7 — 12.7 4.5 — 4.5 0.4 — 0.4 17.6 — 17.6 Other 0.3 — 0.3 0.3 — 0.3 Adjusted EBITDA (Non-GAAP) $ 241.9 $ 92.3 $ (24.8) $ 309.4 21
Page 22
22